Impaired drug absorption due to high stomach pH: A review of strategies for mitigation of such effect to enable pharmaceutical product development

Molecular Pharmaceutics

Volumn 10, Issue 11, 2013, Pages 3970-3979

  Mitra, Amitava ^a   Kesisoglou, Filippos ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

achlorhydria; dissolution; dog study; famotidine; modeling; pharmacokinetics; simulation

Indexed keywords

ALBENDAZOLE; ALENDRONIC ACID; ATAZANAVIR; AZD 8055; CEFPODOXIME; DIGOXIN; DIPYRIDAMOLE; ENOXACIN; FAMOTIDINE; ITRACONAZOLE; KETOCONAZOLE; LANSOPRAZOLE; NIFEDIPINE; OMEPRAZOLE; PENTAGASTRIN; POSACONAZOLE; RALTEGRAVIR; RANITIDINE;

ACHLORHYDRIA; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MALABSORPTION; DRUG SCREENING; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; MALABSORPTION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW; STOMACH ACID SECRETION; STOMACH CONTENT; STOMACH EMPTYING; STOMACH PH;

ABSORPTION; ACHLORHYDRIA; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DOGS; FAMOTIDINE; HUMANS; HYDROGEN-ION CONCENTRATION; STOMACH;

EID: 84887358671     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400256h     Document Type: Review

References (51)

1. Lahner, E.; Annibale, B.; Delle-Fave, G. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy Alimentary Pharmacol. Ther. 2009, 29, 1219-1229
2. McColl, K. E. L.; El-Omar, E.; Gillen, D. Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy Br. Med. Bull. 1998, 54 (1) 121-138
3. Morihara, M.; Aoyagi, N.; Kaniwa, N.; Kojima, S.; Ogata, H. Assessment of gastric acidity of Japanese subjects over last 15 years Biol. Pharm. Bull. 2001, 24 (3) 313-315
4. Russell, T. L.; Berardi, R. R.; Barnett, J. L.; Dermentzoglou, L. C.; Jarvenpaa, K. M.; Schmaltz, S. P.; Dressman, J. B. Upper gastrolintestinal pH in seventy nine healthy, elderly, north American men and women Pharm. Res. 1993, 10 (2) 187-196
5. DeVault, K. R.; Talley, N. J. Insights into the future of gastric acid suppression Nat. Rev. Gastroenterol. Hepatol. 2009, 6 (9) 524-532
6. Smolka, A. J.; Backret, S. How helicobacter pylori infection controls gastric acid secretion J. Gastroenterology. 2012, 47 (6) 609-618
7. Lake-Bakaar, G.; Quadros, E.; Beidas, S.; Elsakr, M.; Tom, W.; Wilson, D. E.; Dincsoy, H. P.; Cohen, P.; Straus, E. Gastric secretory failure in patients with the acquired immunodeficiency syndrome (AIDS) Ann. Intern. Med. 1988, 109, 502-504
8. Herzlich, B. C.; Schiano, T. D.; Moussa, Z.; Zimbalist, E.; Panagopoulos, G.; Ast, A.; Nawabi, I. Decreased intrinsic factor secretion in AIDS: relation to parietal cell acid secretory capacity and vitamin B12 malabsorption Am. J. Gastroenterol. 1992, 87 (12) 1781-1788
9. Russell, T. L.; Berardi, R. R.; Barnett, J. L.; O'Sullivan, T. L.; Wagner, J. G.; Dressman, J. B. pH-related changes in the absorption of dipyridamole in the elderly Pharm. Res. 1994, 11 (1) 136-143
10. Krishna, G.; Moton, A.; Ma, L.; Medlock, M. M.; McLeod, J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers Antimicrob. Agents Chemother. 2009, 53 (3) 958-966
11. Carlson, J. A.; Mann, H. J.; Canafax, D. M. Effect of pH on disintegration and dissolution of ketoconazole tablets Am. J. Hosp. Pharm. 1983, 40 (8) 1334-1336
12. Zhou, R.; Moench, P.; Heran, C.; Lu, X.; Mathias, N.; Faria, T. N.; Wall, D. A.; Hussain, M. A.; Smith, R. L.; Sun, D. pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model Pharm. Res. 2005, 22 (2) 188-192
13. Chin, T. W. F.; Loeb, M.; Fong, I. W. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole Antimicrob. Agents Chemother. 1995, 39 (8) 1671-1675
14. Piscitelli, S. C.; Goss, T. F.; Wilton, J. H.; D'Andrea, D. T.; Goldstein, H.; Schentag, J. J. Effects of ranitidine and sucralfate on ketoconazole bioavailability Antimicrob. Agents Chemother. 1991, 35 (9) 1765-1771
15. Walravens, J.; Brouwers, J.; Spriet, I.; Tack, J.; Annaert, P.; Augustijns, P. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations Clin. Pharmacokinet. 2011, 50 (11) 725-734
16. Tomilo, D. L.; Smith, P. F.; Ogundele, A. B.; Difrancesco, R.; Berenson, C. S.; Eberhardt, E.; Bednarczyk, E.; Morse, G. D. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers Pharmacotherapy 2006, 26, 341-346
17. Reyataz prescribing information. http://packageinserts.bms.com/pi/pi- reyataz.pdf.
18. Sanaka, M.; Yamamoto, T.; Kuyama, Y. Effects of proton pump inhibitors on gastric emptying: a systematic review Dig. Dis. Sci. 2010, 55 (9) 2431-2440
19. Ogawa, R.; Echizen, H. Clinically significant drug interactions with antacids: an update Drugs 2011, 71 (14) 1839-1864
20. Sadowski, D. C. Drug interactions with antacids. Mechanisms and clinical significance Drug Saf. 1994, 11 (6) 395-407
21. Porras, A. G.; Holland, S. D.; Gertz, B. J. Pharmacokinetics of Alendronate Clin. Pharm. 1999, 36 (5) 315-328
22. Fosamax prescribing information. http://www.merck.com/product/usa/pi- circulars/f/fosamax/fosamax-pi.pdf.
23. Iwamoto, M.; Wenning, L. A.; Nguyen, B. Y.; Teppler, H.; Moreau, A. R.; Rhodes, R. R.; Hanley, W. D.; Jin, B.; Harvey, C. M.; Breidinger, S. A.; Azrolan, N.; Farmer, H. F.; Isaacs, R. D.; Chodakewitz, J. A.; Stone, J. A.; Wagner, J. A. Effects of omeprazole on plasma levels of raltegravir Clin. Infect. Dis. 2009, 15 48 (4) 489-492
24. Gertz, B. J.; Holland, S. D.; Kline, W. F.; Matuszewski, B. K.; Freeman, A.; Quan, H.; Lasseter, K. C.; Mucklow, J. C.; Porras, A. G. Studies of the oral bioavailability of alendronate Clin. Pharmacol. Ther. 1995, 58 (3) 288-298
25. Cohen, A. F.; Kroon, R.; Schoemaker, R.; Hoogkamer, H.; Van Vliet, A. Influence of gastric acidity on the bioavailability of digoxin Ann. Intern. Med. 1991, 34 (Suppl. 1) S67-S71
26. Soons, P. A.; van den Berg, G.; Danhof, M.; van Brummelen, P.; Jansen, J. B.; Lamers, C. B.; Breimer, D. D. Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects Eur. J. Clin. Pharmacol. 1992, 42 (3) 319-324
27. Polster, C. S.; Atassi, F.; Wu, S. J.; Sperry, D. C. Use of artificial stomach-duodenum model for investigation of dosing fluid effect on clinical trial variability Mol. Pharmaceutics 2010, 7 (5) 1533-1538
28. Badawy, S. I. F.; Hussain, M. A. Microenvironmental pH modulation in solid dosage forms J. Pharm. Sci. 2007, 96, 948-959
29. Mitra, A.; Kesisoglou, F.; Beauchamp, M.; Zhu, W.; Chiti, F.; Wu, Y. Using absorption simulation and gastric pH modulated dog model for formulation development to overcome achlorhydria effect Mol. Pharmaceutics 2011, 8 (6) 2216-2223
30. Badawy, S. I. F.; Gray, D. B.; Zhao, F.; Sun, D.; Schuster, A. E.; Hussain, M. A. Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389 Pharm. Res. 2006, 23 (5) 989-996
31. Taniguchi, C.; Inoue, R.; Kawabata, Y.; Yamashita, K.; Wada, K.; Yamauchi, Y.; Yamada, S.; Onoue, S. Novel formulations of dipyridamole with microenvironmental pH-modifiers for improved dissolution and bioavailability under hypochlorhydria Int. J. Pharm. 2012, 434 (1-2) 148-154
32. Siepe, S.; Lueckel, B.; Kramer, A.; Ries, A.; Gurny, R. Assessment of tailor-made HPMC-based matrix minitablets comprising a weakly basic drug compound Drug Dev. Ind. Pharm. 2008, 34 (1) 46-52
33. Alam, M. A.; Ali, R.; Al-Jenoobi, F. I.; Al-Mohizea, A. M. Solid dispersions: a strategy for poorly aqueous soluble drugs and technology updates Expert Opin. Drug Delivery 2012, 9 (11) 1419-1440
34. Tran, P. H.; Tran, T. T.; Lee, K. H.; Kim, D. J.; Lee, B. J. Dissolution-modulating mechanism of pH modifiers in solid dispersion containing weakly acidic or basic drugs with poor water solubility Expert Opin. Drug Delivery 2010, 7 (5) 647-661
35. Sugawara, M.; Kadomura, S.; He, X.; Takekuma, Y.; Kohri, N.; Miyazaki, K. The use of an in vitro dissolution and absorption system to evaluate oral absorption of two weak bases in pH-independent controlled-release formulations Eu. J. Pharm. Sci. 2005, 26 (1) 1-8
36. Kohri, N.; Yamayoshi, Y.; Xin, H.; Iseki, K.; Sato, N.; Todo, S.; Miyazaki, K. Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique J. Pharm. Pharmacol. 1999, 51 (2) 159-164
37. Dickinson, P. A.; Abu Rmaileh, R.; Ashworth, L.; Barker, R. A.; Burke, W. M.; Patterson, C. M.; Stainforth, N.; Yasin, M. An investigation into the utility of a multi-compartmental, dynamic, system of the upper gastrointestinal tract to support formulation development and establish bioequivalence of poorly soluble drugs AAPS J. 2012, 14 (2) 196-205
38. Kalantzi, L.; Goumas, K.; Kalioras, V.; Abrahamsson, B.; Dressman, J. B.; Reppas, C. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies Pharm. Res. 2006, 23 (1) 165-176
39. Porter, C. J.; Trevaskis, N. L.; Charman, W. N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discovery 2007, 6 (3) 231-248
40. Onoue, S.; Inoue, R.; Taniguchi, C.; Kawabata, Y.; Yamashita, K.; Wada, K.; Yamauchi, Y.; Yamada, S. Improved dissolution and pharmacokinetic behavior of dipyridamole formulation with microenvironmental pH-modifier under hypochlorhydria Int. J. Pharm. 2012, 426 (1-2) 61-66
41. Bhattachar, S. N.; Perkins, E. J.; Tan, J. S.; Burns, L. J. Effect of gastric pH on the pharmacokinetics of a BCS class II compound in dogs: utilization of an artificial stomach and duodenum dissolution model and GastroPlus, simulations to predict absorption J. Pharm. Sci. 2011, 100 (11) 4756-4765
42. Fancher, R. M.; Zhang, H.; Sleczka, B.; Derbin, G.; Rockar, R.; Marathe, P. Development of a canine model to enable the preclinical assessment of pH-dependent absorption of test compounds J. Pharm. Sci. 2011, 100 (7) 2979-2988
43. Polentarutti, B.; Albery, T.; Dressman, J.; Abrahamsson, B. Modification of gastric pH in the fasted dog J. Pharm. Pharmacol. 2010, 62 (4) 462-469
44. Chen, E. P.; Mahar Doan, K. M.; Portelli, S.; Coatney, R.; Vaden, V.; Shi, W. Gastric pH and gastric residence time in fasted and fed conscious cynomolgus monkeys using the Bravo pH system Pharm. Res. 2008, 25 (1) 123-134
45. Kondo, H.; Shinoda, T.; Nakashima, H.; Watanabe, T.; Yokohama, S. Characteristics of the gastric pH profiles of unfed and fed cynomolgus monkeys as pharmaceutical product development subjects Biopharm. Drug Dispos. 2003, 24 (1) 45-51
46. Kohri, N.; Yamayoshi, Y.; Iseki, K.; Sato, N.; Todot, S.; Miyazaki, K. Effect of gastric pH on the bioavailability of albendazole in rabbits Pharm. Pharmacol. Commun. 1998, 4, 267-270
47. Kohri, N.; Miyata, N.; Takahashi, M.; Endo, H.; Iseki, K.; Miyazaki, K.; Takechiand, S.; Nomura, A. Evaluation of pH-independent sustained-release granules of dipyridamole by using gastric-acidity-controlled rabbits and human subjects Int. J. Pharm. 1992, 81, 49-58
48. Wada, I.; Otaka, M.; Jin, M.; Odashima, M.; Komatsu, K.; Konishi, N.; Matsuhashi, T.; Horikawa, Y.; Ohba, R.; Itoh, H.; Watanabe, S. Expression of HSP72 in the gastric mucosa is regulated by gastric acid in rats-correlation of HSP72 expression with mucosal protection Biochem. Biophys. Res. Commun. 2006, 349, 611-618
49. Kesisoglou, F.; Wu, Y. Understanding the effect of API properties on bioavailability through absorption modeling AAPS J. 2008, 10 (4) 516-525
50. Heimbach, T.; Xia, B.; Lin, T. H.; He, H. Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data AAPS J. 2013, 15 (1) 143-158
51. Rose, J. P. Effective absorption modeling in relative bioavailability study risk assessment AAPS J. 2012, 14 (4) 895-903